JT
Jubilant Therapeutics develops selective small molecule modulators targeting genetically-defined cancers and autoimmune disorders, focusing on specific genetic mutations and drug resistance mechanisms. The company aims to meet unmet medical needs by advancing its clinical-stage programs through strategic partnerships and fast-tracking them from discovery to pivotal studies.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Jubilant Therapeutics develops selective small molecule modulators targeting genetically-defined cancers and autoimmune disorders, focusing on specific genetic mutations and drug resistance mechanisms. The company aims to meet unmet medical needs by advancing its clinical-stage programs through strategic partnerships and fast-tracking them from discovery to pivotal studies.